Q3 2024 Holdings
Filed 2024-11-14 | 108 holdings | $4.7B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $324.7M | 3,888,669 | 6.9% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $304.8M | 2,979,235 | 6.4% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $299.7M | 28,057,456 | 6.3% |
| Iovance Biotherapeutics Inc(IOVA) | COM | 462260100 | $249.9M | 26,617,709 | 5.3% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $231.7M | 2,027,608 | 4.9% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $186.5M | 3,560,214 | 3.9% |
| Verona Pharma PLC(VRNA) | SPONSORED ADS | 925050106 | $181.7M | 6,315,933 | 3.8% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $161.8M | 3,204,976 | 3.4% |
| Intra-Cellular Therapies Inc(ITCIEUR) | COM | 46116X101 | $118.7M | 1,622,215 | 2.5% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $118.4M | 2,015,007 | 2.5% |
| Viking Therapeutics Inc(VKTX) | COM | 92686J106 | $107.6M | 1,699,987 | 2.3% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $100.5M | 6,282,290 | 2.1% |
| Immatics N.v(IMTX) | SHS | N44445109 | $92.3M | 8,086,159 | 2.0% |
| Evolus Inc(EOLS) | COM | 30052C107 | $86.8M | 5,356,622 | 1.8% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $84.5M | 2,872,547 | 1.8% |
| Artivion Inc(AORT) | COM | 228903100 | $74.4M | 2,793,703 | 1.6% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $74.2M | 1,485,232 | 1.6% |
| Astria Therapeutics Inc(CATBUSD) | COM | 04635X102 | $71.4M | 6,485,420 | 1.5% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $70.4M | 782,844 | 1.5% |
| Applied Therapeutics Inc(APLT) | COM | 03828A101 | $68.0M | 8,005,000 | 1.4% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $68.0M | 3,683,004 | 1.4% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $67.8M | 2,378,762 | 1.4% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $67.0M | 1,164,035 | 1.4% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $64.4M | 118,839 | 1.4% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $64.0M | 2,812,665 | 1.4% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $62.2M | 2,330,294 | 1.3% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $61.9M | 1,374,563 | 1.3% |
| Meiragtx Hldgs PLC(MGTX) | COM | G59665102 | $52.4M | 12,581,103 | 1.1% |
| Aldeyra Therapeutics Inc(ALDX) | COM | 01438T106 | $50.0M | 9,275,851 | 1.1% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $49.2M | 1,714,806 | 1.0% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $48.1M | 6,906,646 | 1.0% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $42.6M | 1,296,416 | 0.9% |
| Spdr SER TR(XBI)Put | S&P BIOTECH | 78464A870 | $39.5M | 400,000 | 0.8% |
| Acrivon Therapeutics Inc(ACRV) | COMMON STOCK | 004890109 | $37.5M | 5,360,858 | 0.8% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $37.0M | 724,698 | 0.8% |
| Nautilus Biotechnology Inc(NAUT) | COM | 63909J108 | $35.9M | 12,594,211 | 0.8% |
| Celcuity Inc(CELC) | COM | 15102K100 | $35.2M | 2,362,279 | 0.7% |
| Insulet Corp(PODD) | COM | 45784P101 | $33.1M | 142,269 | 0.7% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $30.3M | 1,235,187 | 0.6% |
| Contineum Therapeutics Inc(CTNM) | CL A | 21217B100 | $29.0M | 1,516,668 | 0.6% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $28.9M | 3,324,468 | 0.6% |
| Intuitive Surgical Inc(ISRG) | COM NEW | 46120E602 | $28.6M | 58,119 | 0.6% |
| Natera Inc(NTRA) | COM | 632307104 | $27.9M | 220,000 | 0.6% |
| CG Oncology Inc(CGON) | COM | 156944100 | $27.7M | 733,695 | 0.6% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $27.4M | 2,180,020 | 0.6% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $25.8M | 718,144 | 0.5% |
| Adagio MED Hldgs Inc(ADGM) | COM | 00534B100 | $25.3M | 9,812,419 | 0.5% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $25.3M | 1,027,749 | 0.5% |
| Procept Biorobotics Corp(PRCT) | COM | 74276L105 | $25.3M | 315,659 | 0.5% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $24.5M | 212,228 | 0.5% |